Abstract CN43
Background
The COVID-19 pandemic has impacted many aspects of the practice of oncology around the world. COVID was first detected in Ireland on 29/2/20. Many oncology units saw dramatic changes in activity in the face of rising infection rates. We aim to assess compare pharmacy activity, day unit systemic therapy adminstration and nursing staffing levels during the pre- and COVID periods.
Methods
Hospital information systems were used to retrieve numbers of patients attending, numbers and types of items dispensed by pharmacy, and available nurses to deliver the systemic therapies from March 2019 to Feb. 2021. The data was analysed to identify trends in prescribing and dispensing practices for this period. Supportive medications such as anti-emetics, bisphosphosphonates were not included. Subgroup analysis on numbers of chemotherapy, immunotherapy, monoclonal antibody drugs dispensed per month was performed. A paired t-test was used to compare means.
Results
9410 non-clinical trials and 411 clinical trials items were dispensed from March 2019 until February 2020 (pre-COVID) for 11,606 patient attendances. From March 2020 until February 2021 (COVID period), 8931 non-clinical trials and 826 clinical trials items were dispensed for 10818 patient attendances. The mean number of non-clinical trials items dispensed per month were 784 and 744 respectively, with no statistical difference being found (p=0.11). There was a doubling in the number of clinical trials agents dispensed. The mean number of nurses available to administer therapies per day was 5.7 (SD=0.78) compared to the projected 7.8 WTE (whole time equivalents) ideally required. Table: CN43
Mean number of dispensed non-clinical trial agents per month per time period
pre-COVID (3/19-2/20) | COVID (3/20-2/21) | p-value | |
Chemotherapy | 598 | 544 | 0.03 |
Immunotherapy | 52 | 57 | 0.29 |
Monoclonal antibodies | 134 | 133 | 0.084 |
Conclusions
Despite COVID restrictions it was possible to administer comparable numbers of cancer treatments throughout the COVID period, when compared to the previous year despite modest nursing staff numbers due to the dedication and selflessness of nursing, oncologists and oncology pharmacy staff.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
CN44 - Exploring cancer patients' and survivors’ experiences of cancer care in COVID-19: A longitudinal qualitative study
Presenter: Maura Dowling
Session: SARS-CoV-2 and cancer (EONS-ECPC)
Resources:
Abstract
Slides
Webcast
EONS RWG: Patients experiences during COVID-19
Presenter: Manuela Eicher
Session: SARS-CoV-2 and cancer (EONS-ECPC)
Resources:
Slides
Webcast
Delays in screening and diagnosis of cancer during COVID: What can we expect for the next years?
Presenter: Urska Kosir
Session: SARS-CoV-2 and cancer (EONS-ECPC)
Resources:
Slides
Webcast
Cancer care in COVID from a patient perspective
Presenter: Alina Comanescu
Session: SARS-CoV-2 and cancer (EONS-ECPC)
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Amanda Drury
Session: SARS-CoV-2 and cancer (EONS-ECPC)
Resources:
Slides
Webcast